SCHEMBL8937330

SCHEMBL8937330

CCCOc1ccc(C(=CC(=O)N2CCN(C(=O)c3cc(OC)c(OC)c(OC)c3)CC2)c2cccc(Cl)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
CYP1A2 P05177 1/20 0.49
MAPT P10636 3/20 0.47
LMNA P02545 1/20 0.47
HSD17B10 Q99714 2/20 0.47
TP53 P04637 2/20 0.47
HPGD P15428 1/20 0.46
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
GAA P10253 1/20 0.44
KCNA5 P22460 1/20 0.43
DRD3 P35462 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937673 1.00 ALDH1A1 (0.51) ALDH1A1L3MBTL1CYP1A2MAPTLMNA
SCHEMBL8937326 1.00 ALDH1A1 (0.51) ALDH1A1L3MBTL1CYP1A2MAPTLMNA
SCHEMBL8937786 0.94 ALDH1A1 (0.50) ALDH1A1L3MBTL1CYP1A2LMNAHSD17B10
SCHEMBL8937280 0.94 ALDH1A1 (0.50) ALDH1A1L3MBTL1CYP1A2LMNAHSD17B10
SCHEMBL8937277 0.94 ALDH1A1 (0.50) ALDH1A1L3MBTL1CYP1A2LMNAHSD17B10
SCHEMBL10436183 0.92 ALDH1A1 (0.50) ALDH1A1L3MBTL1CYP1A2MAPTLMNA
SCHEMBL8937348 0.92 HPGD (0.53) ALDH1A1L3MBTL1CYP1A2LMNAHSD17B10
SCHEMBL8937351 0.92 HPGD (0.53) ALDH1A1L3MBTL1CYP1A2LMNAHSD17B10
SCHEMBL8937783 0.92 HPGD (0.56) ALDH1A1L3MBTL1CYP1A2LMNAHSD17B10
SCHEMBL8937787 0.92 HPGD (0.56) ALDH1A1L3MBTL1CYP1A2LMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US claimed
EP-0395446-B1 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists SANKYO CO (JP) 1995-03-01 EP claimed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US claimed
EP-0395446-A2 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists Sankyo Company Limited (JP) 1990-10-31 EP claimed
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US disclosed
US-5556852-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
EP-0395446-B1 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists SANKYO CO (JP) 1995-03-01 EP disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 US disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US disclosed
EP-0395446-A2 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists Sankyo Company Limited (JP) 1990-10-31 EP disclosed